ArticleMycopathologia2019
Antifungal Activity of Essential Oils Against Candida Species Isolated from Clinical Samples.
Article in Mycopathologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Meta-analysis of the antifungal activities of three essential oils as alternative therapies in dermatophytosis infections.Journal of applied microbiology · 2022Pooled it
- Effect of thymus vulgaris essential oil as an antifungal agent on the flexural strength, surface roughness, and color stability of polymethyl methacrylate acrylic resin.Scientific reports · 2026Article
- Characterization and Antifungal Activity of Essential oil of Cymbopogon citratus: Special Emphasis on Preliminary Fungicidal Mechanisms against Candida auris and Cryptococcus neoformans.Current microbiology · 2026Article
- Cell Wall Proteome ofPathogens (Basel, Switzerland) · 2026Article
- TargetingInternational journal of molecular sciences · 2025Article
- Development and Evaluation of Microencapsulated Oregano Essential Oil as an Alternative Treatment forACS applied materials & interfaces · 2024Article
- Essential Oils againstAntibiotics (Basel, Switzerland) · 2024Review
- From plants to particles: herbal solutions and nanotechnology combating resistant vulvovaginal candidiasis.Therapeutic delivery · 2024Review
- The Formulation and Evaluation ofGels (Basel, Switzerland) · 2023Article
- Antifungal and Antibiofilm Activity of Colombian Essential Oils against DifferentAntibiotics (Basel, Switzerland) · 2023Article
- Chemical Composition and Antimicrobial Potential of Essential Oil ofPharmaceuticals (Basel, Switzerland) · 2022Article
- In Vitro Activity of Essential Oils Distilled from Colombian Plants againstMolecules (Basel, Switzerland) · 2022Article
- Reassessing the Use of Undecanoic Acid as a Therapeutic Strategy for Treating Fungal Infections.Mycopathologia · 2021Review
- Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The Effect of Ten Essential Oils on Several Cutaneous Drug-Resistant Microorganisms and Their Cyto/Genotoxic and Antioxidant Properties.Molecules (Basel, Switzerland) · 2019Article
- Enhanced Killing ofMolecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the in vitro antifungal activity of essential oils obtained from the aromatic plants Laurus nobilis, Thymus vulgaris, Mentha piperita, Cymbopogon citratus and Lippia junelliana against the following Candida species isolated from clinical samples: C. krusei (n = 10); C. albicans (n = 50); C. glabrata (n = 70) and C. parapsilosis (n = 80). The minimal inhibitory concentration (MIC) was determined according to EDef 7.3.1 document from EUCAST. Amphotericin B and fluconazole were the antifungal drugs used as inhibition control. The concentration ranges evaluated were 0.4-800 and 0.03-128 mg l
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.